A Phase 3 interventional study of Bupivacaine in Fracture of Lower Limb, sponsored by Cristália Produtos Químicos Farmacêuticos Ltda.. Withdrawn at 2 sites in Brazil. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-26.
Sponsored by Cristália Produtos Químicos Farmacêuticos Ltda. · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the non-inferiority between Heavy Levobupivacaine with Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine During Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.
The Heavy Levobupivacaine with Enantiomeric Excess of 50% was developed to be a safe local anesthetic replacing the Heavy Racemic Bupivacaine.
This study will evaluate the non-inferiority regarding efficacy and safety of spinal anesthesia in orthopedic procedures.
Cristália Produtos Químicos Farmacêuticos Ltda. is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 ml for subarachnoid block
Drug: Bupivacaine
3 ml subarachnoid block
Drug: Bupivacaine
single dose of 15mg by a slow injection rate of 1 ml/s
Also known as: marcaine
Time of latency for sensory block at T10 dermatome.
Evaluate the sensory block at T10 after the anesthetic injection through sensory stimulation by needle.
Time frame: +/- 40 min after injection
Sensory block duration
Verifying the duration of anesthesia from after puncture till the presence of positive sensitivity by needle stimulation region of the foot.
Time frame: +/- 3 hours
Motor Block Evaluation
Motor block evaluation by Bromage Scale every five minutes after puncture till 20 minutes.
Time frame: +/- 30 min
Maximum cranial dispersion verifying the largest metamer achieved.
Evaluated by needle stimulation every 2 minutes from the removal of post-puncture needle until the maximum extension time.
Time frame: +/- 45 min
Evaluation of the cardiocirculatory and respiratory parameters
Systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and oxygen saturation (SpO2) are evaluate during the study to measure the safety of cardiocirculatory and respiratory parameters
Time frame: +/- 8 hours
Time of regression of motor block by Bromage Scale
Will be measure the time of recovery of the motor block, the patient have to score note 4 of the Bromage Scale
Time frame: +/- 9 - 10 hours
The residual analgesic effect
Will be evaluated the end of the analgesic effect of the anesthetic solution when the patient asks for pain medication.
Time frame: +/- 9-10 hours
Anesthetic failure
Evaluation of the anesthetic failure (if occur)
Time frame: +/- 45 min
Adverse Events
During the study will be evaluate the presence of adverse event due to the anesthetic.
Time frame: +/- 8 - 12 hours
This study is withdrawn, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine
Cristália Produtos Químicos Farmacêuticos Ltda.